Core Viewpoint - Novo Nordisk (NVO.US) experienced a significant decline of 16.43% in stock price, closing at $39.63, and continued to drop by 2.12% in pre-market trading, reaching $38.79, following the announcement of clinical data for CagriSema which did not meet its primary efficacy endpoint in the REDEFINE 4 trial [1][1][1] Group 1: Clinical Trial Results - The clinical trial for CagriSema demonstrated a weight reduction effect of 23% [1] - However, the results did not achieve the predefined primary goal of being non-inferior to Eli Lilly's Tirzepatide [1] Group 2: Stock Performance - The stock's highest price in the last trading session was $41.09, with a lowest price of $39.34 [1] - The trading volume was 98.664 million shares, with a total market capitalization of $176.948 billion [1] - The stock's price-to-earnings ratio (P/E) is reported at 10.90, and the price-to-book ratio (P/B) is 5.778 [1]

Core Viewpoint - The U.S. stock market opened lower with significant fluctuations, while the storage concept Sandisk rose by 5%, contrasting with the mixed performance of major tech stocks, where Nvidia increased by over 1% and Tesla, Microsoft, and Amazon fell by more than 2% [1] Group 1: Stock Performance - The three major U.S. stock indices experienced a low opening and volatility [1] - Sandisk, a storage concept stock, led the gains with a rise of 5% [1] - Major tech stocks showed a mixed performance, with Nvidia up over 1% and Tesla, Microsoft, and Amazon down more than 2% [1] Group 2: Software Sector - The software sector faced a significant decline, with AppLovin dropping over 8% [1] - DoorDash saw a decrease of over 7%, while Palantir and CrowdStrike fell by more than 5% [1] - Other companies like ServiceNow and Datadog also experienced declines of over 4% [1] Group 3: Pharmaceutical Sector - Novo Nordisk's stock plummeted by 14% after the company reported that its weight loss drug Cagrisema was less effective than Eli Lilly's Zepbound [1] - In contrast, Eli Lilly's stock rose by 3% following this news [1]